Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-07-03	JP¥33.00	0.00%	1,759,800
26-07-02	JP¥33.00	0.00%	467,400
26-07-01	JP¥33.00	0.00%	596,600
26-06-30	JP¥33.00	+3.12%	737,300
26-06-29	JP¥32.00	+6.67%	1,163,400

Delayed Quote Japan Exchange

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-07-03 EDT			5-day change	1st Jan Change
33.00 ^JPY	0.00%		+10.00%	-41.07%

06-11	Modalis Therapeutics Corporation announced that it has received ¥2.64 million in funding from Evolution Capital Management LLC	CI
05-26	Modalis Therapeutics Corporation announced that it expects to receive ¥2.64 million in funding from Evolution Capital Management LLC	CI

Market Cap	3.18B 19.71M 17.23M 15.84M 14.76M 28M 1.88B 28.42M 190M 73.91M 923M 73.99M 72.4M	P/E 2024	-3.57x	P/E 2025	-2.01x
Enterprise Value	367M 2.28M 1.99M 1.83M 1.7M 3.23M 217M 3.28M 21.95M 8.53M 107M 8.54M 8.36M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	90.44%	Yield 2024 *	-	Yield 2025	-

06-11	Modalis Therapeutics Corporation announced that it has received ¥2.64 million in funding from Evolution Capital Management LLC	CI
05-26	Modalis Therapeutics Corporation announced that it expects to receive ¥2.64 million in funding from Evolution Capital Management LLC	CI
05-13	Modalis Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
02-12	Modalis Therapeutics Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-08-25	Modalis Therapeutics Corporation announced that it has received ¥3.072 million in funding from Evolution Capital Management LLC	CI
25-08-06	Modalis Therapeutics Corporation announced that it expects to receive ¥3.072 million in funding from Evolution Capital Management LLC	CI
25-07-06	Modalis Therapeutics Licenses Gene Therapy IP from Broad Institute for Muscular Dystrophy Treatment	MT
25-06-15	Modalis Issues Restricted Stock to Subsidiary Employee Under Incentive Plan	MT
25-06-09	SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy	CI
25-04-30	Modalis Issues 21,900 Shares for Restricted Stock Remuneration	MT
25-01-27	Modalis Therapeutics Secures Japanese Patent for Gene Therapy	MT
25-01-06	JCR Pharmaceuticals and Modalis Therapeutics Advance Gene Therapy Research for CNS Disease	MT
25-01-05	Jcr Pharmaceuticals Co., Ltd. and Modalis Therapeutics Corporation Announces Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy	CI

12-24	Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD	BU
25-05-12	Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.	BU
25-01-05	JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy	BU
24-10-28	Modalis Therapeutics - MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a has been granted Orphan Drug Designation in the US by the Food and Drug Administration	AQ
24-10-25	Modalis Therapeutics has received an Orphan Drug Designation from the U.S. Food and Drug Administration for MDL-101, a treatment for congenital muscular dystrophy type 1A (LAMA2-CMD).	BU

Modalis Therapeutics Corporation Stock

Stocks

4883

JP3922600006

Biotechnology & Medical Research

Valuation: Modalis Therapeutics Corporation

Chart: Modalis Therapeutics Corporation

Latest news : Modalis Therapeutics Corporation

Press Releases: Modalis Therapeutics Corporation

Quotes and Performance

Course Extremes

Managers and Directors: Modalis Therapeutics Corporation

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	+10.00%
1 month	-19.51%
3 months	-42.11%
6 months	-41.07%
Current year	-41.07%

Manager	Title	Age	Since
Haru Morita CEO	Chief Executive Officer	56	2015-12-31
Naoki Kobayashi DFI	Director of Finance/CFO	62	-
Tetsuya Yamagata CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Joseph McCracken BRD	Director/Board Member	72	2018-07-31
Toshio Furuta BRD	Director/Board Member	64	2018-11-30
Haru Morita BRD	Director/Board Member	56	2015-12-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-09-23	Osamu Nureki	Others	Founder	64,400	0.1419%
24-09-23	Osamu Nureki	Others	Founder	375,600	0.8278%
24-09-23	Osamu Nureki	Others	Founder	6,000	0.0132%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MODALIS THERAPEUTICS CORPORATION	0.00%	+10.00%	-58.75%	-88.13%	19.71M
ARGENX SE	+0.68%	+5.92%	+80.45%	+137.78%	59.1B
WUXI APPTEC CO., LTD.	+2.32%	+5.03%	+75.51%	+94.88%	55.19B
BIONTECH SE	+3.86%	+6.93%	-11.32%	-9.53%	24.67B
INSMED INCORPORATED	+4.30%	+7.95%	+14.11%	+437.83%	24.19B
WUXI BIOLOGICS (CAYMAN) INC.	+4.74%	+13.68%	+45.58%	-1.42%	19.69B
GENMAB A/S	-0.29%	+9.78%	+44.62%	-27.94%	17.56B
PHARMAESSENTIA CORPORATION	0.00%	+20.78%	+178.93%	+360.74%	16.22B
EXELIXIS, INC.	+3.50%	+1.97%	+21.02%	+191.95%	14.04B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.72%	+19.38%	+42.82%	-	14.84B
Average	+2.58%	+8.71%	+43.30%	+121.80%	24.55B
Weighted average by Cap.	+2.46%	+6.47%	+59.05%	+137.69%

	2024	2025
Net sales	-	-
Net income	-1.32B -8.17M -7.14M -6.56M -6.12M -11.6M -778M -11.77M -78.76M -30.62M -382M -30.65M -29.99M	-2.15B -13.34M -11.66M -10.72M -9.99M -18.95M -1.27B -19.24M -129M -50.03M -625M -50.09M -49.01M
Net Debt	-3.58B -22.17M -19.38M -17.81M -16.6M -31.48M -2.11B -31.96M -214M -83.11M -1.04B -83.2M -81.42M	-2.81B -17.44M -15.24M -14.01M -13.06M -24.76M -1.66B -25.14M -168M -65.37M -816M -65.45M -64.04M

1 week	30	36
1 month	30	39
Current year	30	83
1 year	30	103
3 years	30	285
5 years	30	1,722
10 years	30	4,070